CARESS
"A new methodology based on an advanced molecular probe for early detection of DPD enzyme deficiency in oncological patients, also enabling a personalised and effective drug management"
| Coordinatore | IRBM SCIENCE PARK SPA
Organization address
address: VIA PONTINA KM 30600 contact info |
| Nazionalità Coordinatore | Italy [IT] |
| Totale costo | 1˙528˙220 € |
| EC contributo | 1˙155˙960 € |
| Programma | FP7-SME
Specific Programme "Capacities": Research for the benefit of SMEs |
| Code Call | FP7-SME-2012 |
| Funding Scheme | BSG-SME |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-05-01 - 2015-06-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
IRBM SCIENCE PARK SPA
Organization address
address: VIA PONTINA KM 30600 contact info |
IT (POMEZIA RM) | coordinator | 410˙611.50 |
| 2 |
AMEDA Labordiagnostik GmbH
Organization address
address: Krenngasse 12 contact info |
AT (Graz) | participant | 291˙148.50 |
| 3 |
ODPM SAS
Organization address
address: RUE MOLL 2 contact info |
FR (ANGERS) | participant | 257˙048.00 |
| 4 |
Optomesures
Organization address
address: enceinte Serres contact info |
FR (Saint Marcel Paulel) | participant | 197˙152.00 |
| 5 |
CONSIGLIO NAZIONALE DELLE RICERCHE
Organization address
address: Piazzale Aldo Moro 7 contact info |
IT (ROMA) | participant | 0.00 |
| 6 |
INSTITUT DE CANCEROLOGIE DE L'OUEST
Organization address
address: RUE MOLL 2 contact info |
FR (ANGERS) | participant | 0.00 |
| 7 |
LABOR S.R.L.
Organization address
address: via della Scrofa 117 contact info |
IT (ROMA) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Amongst all the chemotherapy agents, 5-FU (fluorouracil) is being in use since 40 years, and is one of the most successful and widely employed in the treatment for breast, colon, and skin cancer, three of the most frequently occurring malignant tumours. In general, 5-FU is relatively well tolerated at standard doses, but there are some important issues that must be duly taken into consideration: 1)Around 8% of patients manifest a genetic variation that leads to a deficiency of an enzyme called Dihydropyrimidine dehydrogenase (DPD) that is crucial for the metabolism and deactivation of 5-FU. This causes several toxic reactions like mucositis, diarrhea, neutropenia, cerebellar ataxia, cerebellar dysfunction, and can even be fatal at the very first dose of 5-FU, with a mortality rate of about 0,5%. About 30% of patients suffer from severe toxicity effects after being treated with 5FU. Despite many approaches have been proposed for DPD deficiency screening, none of the current strategies are adequate to mandate routine DPD testing prior to starting a 5-FU based therapy. The CARESS project proposes to implement the first, compact, cheap, accurate and standard system for measuring the DPD activity level, thus allowing for fast screening of DPD deficiency and for real time adjusting the therapy administered to the patient through a pharmacokinetic approach, allowing to maximise the therapeutic efficacy, abating the costs associated to the management of the therapy and, most importantly, to limit the dangerous side effects for the patients. The system will take as input a small blood sample and will rely on the chemical interaction between a 5-FU analogous chemical probe with the sample, which will release in the solution ions that can be easily detected and measured through optical analysis.'
Introduzione (Teaser)
Assessing and predicting the efficacy and toxicity of cancer chemotherapy during the course of treatment would be extremely beneficial. European scientists are very close to accomplishing this with an enzyme detector device.